SOFTMEDX-NEW：2019InterimReport.pdf

1、INTERIM REPORT2019CONTENTSPagesCorporate Information2Management Discussion and Analysis3Other Information5Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income7Condensed Consolidated Statement of Financial Position8Condensed Consolidated Statement of Changes in Equity9Con

2、densed Consolidated Statement of Cash Flows9Notes to the Condensed Consolidated Financial Statements10SoftMedx Healthcare Limited2CORPORATE INFORMATIONBOARD OF DIRECTORSExecutive DirectorsCHEUNG Wai KwanWANG JianguoIndependent Non-executive DirectorsHU XuezhenLIN PinzhuoYIU Chun WingAUDIT COMMITTEEY

3、IU Chun Wing(Chairperson)HU XuezhenLIN PinzhuoNOMINATION COMMITTEELIN Pinzhuo(Chairperson)HU XuezhenYIU Chun WingREMUNERATION COMMITTEEHU Xuezhen(Chairperson)LIN PinzhuoYIU Chun WingRISK MANAGEMENT COMMITTEEYIU Chun Wing(Chairperson)LIN PinzhuoWANG JianguoCOMPANY SECRETARYLAM Sung Him,GastonSTOCK CO

4、DE648REGISTERED OFFICELevel 38,Infinitus Plaza199 Des Voeux RoadCentralHong KongSHARE REGISTRARTricor Tengis Limited17/F,Far East Finance Centre16 Harcourt RoadHong KongPRINCIPAL BANKERSBank of China(Hong Kong)LimitedThe Hong Kong and Shanghai Bank Corporation LimitedAUDITORSCL Partners CPA LimitedC

5、ertified Public AccountantsWEBSITE ADDRESS.hkInterim Report 20193MANAGEMENT DISCUSSION AND ANALYSISREVIEW OF FINANCIAL RESULTSSoftMedx Healthcare Limited(the“Company”,together with its subsidiaries,the“Group”)is principally engaged in medical and well-being business.The Group recorded revenue of HK$

6、23.9 million for the six months ended 30 June 2019(2018:HK$26.5 million)with gross profit of HK$12.6 million(2018:HK$14.0 million)and gross profit margin of 52.8%(2018:52.9%).The Groups consolidated loss and consolidated loss attributable to the owners of the Company amounted to HK$25.0 million(2018